DES (drug-eluting stents) market prompts Johnson and Johnson into Cordis move
This article was originally published in Clinica
As part of Johnson and Johnson's plan to improve overall cost structure, its cardiovascular group company Cordis will undergo job cuts and a re-modelling of its business strategy. The Miami Lakes, Florida company is looking to address the changing market aspects for drug-eluting stents (DESs) and also enhance it patient treatment, whilst reducing its cost base. Sales of its Cypher drug-coated stents fell by 41% in the second quarter of 2007, according to J&J. Company chairman and CEO William Weldon assured patients and employees that the group still sees Cordis as an integral part of its business. "We remain committed to the drug-eluting stent market, and we have new products in development across our cardiovascular franchises," said Mr Weldon.